TAU finds pressure chamber therapy is effective in the treatment of autism
Treatment may significantly improve social abilities and the condition of the autistic brainSupport this research
A new Tel Aviv University (TAU) study finds that pressure chamber therapy succeeded in significantly improving social skills and the condition of the autistic brain. The study was conducted on animal models of autism.
The researchers identified changes in the brain, including a reduction in neuroinflammation, which is known to be associated with autism. Moreover, a significant improvement was found in the social functioning of the animal models treated in the pressure chamber. The study’s success has many implications regarding the applicability and understanding of treating autism using pressure chamber therapy.
The breakthrough was made under the leadership of doctoral student Inbar Fischer from the laboratory of Dr. Boaz Barak of TAU’s Sagol School of Neuroscience and School of Psychological Sciences. The research was published in September 2022 in the International Journal of Molecular Sciences.
Fischer and Dr. Barak explain that hyperbaric medicine is a form of therapy in which patients are treated in special chambers where the atmospheric pressure is higher than the pressure we experience at sea level. In addition, they are delivered 100 percent oxygen to breathe. Hyperbaric medicine is considered safe and is already being used to treat a long list of medical conditions. In recent years, scientific evidence has been accumulating that unique protocols of hyperbaric treatments improve the supply of blood and oxygen to the brain, thereby improving brain function.
“The medical causes of autism are numerous and varied, and ultimately create the diverse autistic spectrum with which we are familiar,” Dr. Barak says. “About 20 percent of autistic cases today are explained by genetic causes, that is, those involving genetic defects, but not necessarily ones that are inherited from the parents. Despite the variety of sources of autism, the entire spectrum of behavioral problems associated with it are still included under the single broad heading of ‘autism,’ and the treatments and medications offered do not necessarily correspond directly to the reason why the autism developed.”
In the preliminary phase of the study, a girl carrying the mutation in the SHANK3 gene, which is known to lead to autism, was treated by Professor Shai Efrati, director of the Sagol Center for Hyperbaric Medicine at the Shamir “Assaf Harofeh” Medical Center, faculty member at TAU’s Sagol School of Neuroscience, and a partner in the study. Upon the completion of a series of treatments in the pressure chamber, it was evident that the girl’s social abilities and brain function had improved considerably.
In the next stage, and in order to understand the success of the treatment more deeply, the team of researchers at Dr. Barak’s laboratory sought to understand what being in a pressurized chamber does to the brain. To this end, the researchers used adult animal models carrying the same genetic mutation in the SHANK3 gene as that carried by the girl who had been treated. The experiment comprised a protocol of 40 one-hour treatments in a pressure chamber, which lasted several weeks.
“We discovered that treatment in the oxygen-enriched pressure chamber reduces inflammation in the brain and leads to an increase in the expression of substances responsible for improving blood and oxygen supply to the brain, and therefore brain function,” Dr. Barak reports. “In addition, we saw a decrease in the number of microglial cells, immune system cells that indicate inflammation, which is associated with autism.
“Beyond the neurological findings, what interested us more than anything was to see whether these improvements in the brain also led to an improvement in social behavior, which is known to be impaired in autistic individuals. To our surprise, the findings showed a significant improvement in the social behavior of the animal models of autism that underwent treatment in the pressure chamber compared to those in the control group, who were exposed to air at normal pressure, and without oxygen enrichment. The animal models that underwent treatment displayed increased social interest, preferring to spend more time in the company of new animals to which they were exposed in comparison to the animal models from the control group.”
“The mutation in the animal models is identical to the mutation that exists in humans,” Fischer says. “Therefore, our research is likely to have clinical implications for improving the pathological condition of autism resulting from this genetic mutation, and likely also of autism stemming from other causes. Because the pressure chamber treatment is non-intrusive and has been found to be safe, our findings are encouraging and demonstrate that this treatment may improve these behavioral and neurological aspects in humans as well, in addition to offering a scientific explanation of how they occur in the brain.”